Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

Rhea-AI Summary

Cytek Biosciences (CTKB) has launched the world's first Enhanced Small Particle (ESP™) Detection Option for its Aurora™ CS cell sorter system. This groundbreaking technology enables detection and sorting of particles as small as 70 nm, including exosomes and extracellular vesicles (EVs). The system builds on Cytek's Full Spectrum Profiling™ technology and allows seamless assay transfer from analyzer to sorter. This advancement is particularly significant for research in drug delivery, cell therapy, disease diagnostics, and vaccine delivery, enabling researchers to analyze materials previously impossible to sort.

Positive

• First-to-market with commercial small particle detection technology for cell sorters
• Technology enables new research capabilities, potentially opening new market opportunities
• System allows seamless assay transfer without panel redesign or detector reconfiguration
• Compatible with conventional flow cytometer assays, minimizing adoption barriers

Negative

• None.

Insights

Tech Expert

The launch of the ESP Detection Option for the Aurora CS system represents a significant technological breakthrough in cell sorting capabilities. The ability to detect and sort particles as small as 70 nanometers opens new research avenues in critical fields like drug delivery and cell therapy. This innovation addresses a major gap in the market, as previous cell sorters couldn't effectively isolate and analyze such small particles.

The commercial potential is substantial, particularly in the rapidly growing exosome research market. The seamless integration with existing Full Spectrum Profiling technology and compatibility with conventional flow cytometry assays positions this product well for market adoption. The technology's versatility in supporting various downstream applications like single-cell RNA sequencing and proteomics enhances its value proposition for research institutions and biotech companies.

Market Research Analyst

This product launch strategically positions Cytek in the expanding extracellular vesicle research market, which has significant growth potential. Being first-to-market with this capability gives Cytek a competitive advantage and potential for increased market share in the cell analysis instrumentation sector. The timing aligns well with increasing research focus on exosomes and their role in various therapeutic applications.

The technology's applications across multiple high-growth research areas - including drug delivery, cell therapy and disease diagnostics - diversifies revenue potential. However, market penetration will depend on pricing strategy and adoption by key research institutions. The ability to upgrade existing Aurora CS systems could drive additional revenue from the installed base.

World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific Discoveries

FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system. This is the first commercially available small particle detector on a cell sorter and offers a significant advancement for rapidly evolving research fields, including in drug delivery, cell therapy, disease diagnostics, circulating tumor cells, regenerative medicine, and vaccine delivery. Researchers can now achieve downstream analysis of materials that were previously unable to be sorted, opening new possibilities for breakthroughs in these areas.

Once regarded as cellular debris, exosomes and extracellular vesicles (EVs) are now recognized as pivotal to cell-to-cell communication, disease progression, and therapeutic delivery. With the surge in research interest driven by technological innovations, EVs have become central to a growing body of scientific publications and clinical trials. With Cytek's ESP Detection Option, particles as small as 70 nm can now be studied and sorted for downstream analysis, giving researchers the ability to characterize the full emission spectra of small particles.

“As the first company to offer the ESP Detection Option on a cell sorter, we are setting a new standard for small particle research,” said Ming Yan, Ph.D., CTO of Cytek Biosciences. “The enhanced capabilities of our Cytek Aurora CS system not only push the boundaries of scientific discovery but also may open up new markets for Cytek. Researchers can now explore areas previously beyond their reach, accelerating both scientific progress and potential commercial opportunities.”

The Cytek Aurora CS system builds on Cytek’s established Full Spectrum Profiling™ (FSP™) technology, known for its ability to resolve and sort even the most complex cell populations with unmatched sensitivity. The system enables seamless assay transfer from analyzer to sorter, without the need to redesign panels or reconfigure detectors, allowing researchers to isolate and study identical cell populations. It also supports downstream applications such as single-cell RNA sequencing, proteomics, and cell biology, making it a versatile tool for researchers who need both flexibility and precision. Furthermore, assays designed on conventional flow cytometers can easily be run on the Cytek Aurora CS system, minimizing disruption while maximizing productivity.

“With the ESP Detection Option, Cytek continues its commitment to innovation, helping researchers tackle the most pressing challenges in biomedical science,” added Yan. “We are positioned at the forefront of exosome and extracellular vesicle research, and plan to continue to deliver cutting-edge tools and technologies that address the unique challenges of studying these nanoscale particles.”

For more information, please visit www.cytekbio.com.

About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle (ESP™) detection technology; the flow cytometer and imaging products under the Amnis^® and Guava^® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek’s business, product plans, strategies and market opportunities; the enhanced product capabilities opening up new markets and potential commercial opportunities for Cytek; and Cytek’s plan to continue to deliver cutting-edge tools and technologies that address the unique challenges of studying nanoscale particles. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to global economic, political and market conditions; competition; market acceptance of Cytek’s current and potential products; Cytek’s dependence on certain sole and single source suppliers; Cytek’s ability to manage the growth and complexity of its organization; Cytek’s ability to manage relationships with key customers and suppliers; Cytek’s ability to retain key employees; and Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com

Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com

FAQ

What is Cytek Biosciences' (CTKB) new ESP Detection Option?

It's the first commercially available small particle detector for cell sorters, enabling detection and sorting of particles as small as 70 nm, including exosomes and extracellular vesicles.

What size particles can Cytek's (CTKB) ESP Detection Option analyze?

The ESP Detection Option can detect and analyze particles as small as 70 nanometers (nm).

What research fields will benefit from Cytek's (CTKB) ESP Detection technology?

The technology benefits research in drug delivery, cell therapy, disease diagnostics, circulating tumor cells, regenerative medicine, and vaccine delivery.

How does Cytek's (CTKB) Aurora CS system with ESP Detection differ from traditional cell sorters?

It's the first to offer small particle detection capabilities, uses Full Spectrum Profiling technology, and allows seamless assay transfer without redesigning panels or reconfiguring detectors.